SCHEMBL29901533

SCHEMBL29901533

Fc1ccc(Cl)cc1-c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.52
CCR5 P51681 2/20 0.52
CCR8 P51685 2/20 0.52
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
PKM P14618 2/20 0.48
GRM5 P41594 4/20 0.47
KDM4E B2RXH2 3/20 0.46
METAP1 P53582 2/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
DOHH Q9BU89 1/20 0.46
P4HTM Q9NXG6 1/20 0.46
TP53 P04637 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28115227 1.00 CCR1 (0.52) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL10330894 0.87 ALDH1A1 (0.50) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL7576751 0.83 CCR1 (0.53) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL5845698 0.83 GRM5 (0.51) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL320090 0.81 TGFBR1 (0.49) CYP1A2TGFBR1
SCHEMBL12377643 0.80 KDM4E (0.54) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL31400260 0.80 KDM4E (0.54) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL24870942 0.80 CCR1 (0.50) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL21164394 0.80 CCR1 (0.50) CCR1CCR5CCR8RAB9ANPC1
SCHEMBL4337883 0.80 CCR1 (0.50) CCR1CCR5CCR8RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2025-05-27 US disclosed
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2023-01-05 US disclosed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 CCR1 3565/4885CCR5 2887/4885CCR8 4001/4885
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 CCR1 3565/4885CCR5 2887/4885CCR8 4001/4885
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NSD2, NSD1, NSD3 CCR1 3565/4885CCR5 2887/4885CCR8 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.